Patient Engagement at a Tipping Point—The Need for Cultural Change Across Patient, Sponsor, and Regulator Stakeholders: Insights From the DIA Conference, “Patient Engagement in Benefit Risk Assessment Throughout the Life Cycle of Medical Products”
Open Access
- 1 September 2016
- journal article
- research article
- Published by Springer Science and Business Media LLC in Therapeutic Innovation & Regulatory Science
- Vol. 50 (5), 546-553
- https://doi.org/10.1177/2168479016662902
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- A Paradigm Shift Towards Patient Involvement in Medicines Development and Regulatory Science: Workshop Proceedings and CommentaryTherapeutic Innovation & Regulatory Science, 2016
- What do pharmaceutical industry professionals in Europe believe about involving patients and the public in research and development of medicines? A qualitative interview studyBMJ Open, 2015
- Engaging Patients Across the Spectrum of Medical Product DevelopmentJAMA, 2015
- Patient Engagement Practices in Clinical Research among Patient Groups, Industry, and Academia in the United States: A SurveyPLOS ONE, 2015
- Partnering With Patients in the Development and Lifecycle of Medicines: A Call for ActionTherapeutic Innovation & Regulatory Science, 2015
- Training on trials: Patients taught the language of drug developmentNature Medicine, 2015
- Transparency and the European Medicines Agency — Sharing of Clinical Trial DataThe New England Journal of Medicine, 2014
- Shared decision making: really putting patients at the centre of healthcareBMJ, 2012
- The Challenge of Shared Decision Making Among Patients With Lower Literacy: A Framework for Research and DevelopmentMedical Decision Making, 2009
- Patient involvement in patient safety: what factors influence patient participation and engagement?Health Expectations, 2007